Immutep Limited is a globally operating clinical-stage biotechnology company developing novel LAG-3 (Lymphocyte Activation Gene-3) immunotherapies for cancer and autoimmune diseases. Headquartered in Sydney, Australia, with major operational and clinical research facilities in Châtenay-Malabry (Paris), France, and Berlin, Germany, the company was built around the foundational LAG-3 discoveries of CSO Dr. Frédéric Triebel. Its lead oncology asset, eftilagimod alfa (efti), is a first-in-class soluble LAG-3 fusion protein acting as an antigen-presenting cell activator targeting MHC Class II, evaluated in combination with checkpoint inhibitors across solid tumors. Following an independent data monitoring committee futility finding for the registrational Phase 3 TACTI-004 trial in 1L non-small cell lung cancer in 2026, Immutep initiated targeted workforce downsizing and trial wind-down to preserve capital and extend its cash runway into 2028 while advancing IMP761, a first-in-class LAG-3 agonist antibody in Phase 1 trials for autoimmune diseases.
Phase 1 clinical trial readout for LAG-3 agonist IMP761 in healthy volunteers and autoimmune indications
Projected cash runway threshold following TACTI-004 trial wind-down and targeted workforce reduction
Following the independent data monitoring committee futility determination and subsequent termination of its registrational Phase 3 TACTI-004 trial evaluating soluble LAG-3 fusion protein eftilagimod alfa (efti) combined with Keytruda (pembrolizumab) and chemotherapy in 1L non-small cell lung cancer (NSCLC), Immutep initiated corporate cost reductions including targeted workforce downsizing and trial wind-down to preserve capital and extend its cash runway (A8.5M / ~4.1M USD) well into H1 CY2028.
Following the futility discontinuation of its Phase 3 TACTI-004 trial for lead soluble LAG-3 candidate eftilagimod alfa in 1L NSCLC, Immutep implemented workforce downsizing and cost reductions to extend cash runway into H1 CY2028.
Chief Executive Officer and Executive Director
Chief Scientific Officer and Executive Director
No active job listings. Check back later.